Short Interest in enGene Holdings Inc. (NASDAQ:ENGN) Decreases By 68.9%

enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) was the target of a significant decline in short interest in April. As of April 30th, there was short interest totalling 22,600 shares, a decline of 68.9% from the April 15th total of 72,700 shares. Based on an average trading volume of 78,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.3% of the company's stock are sold short.

Insider Buying and Selling

In other enGene news, major shareholder De Solidarite Des Travai Fonds sold 47,854 shares of enGene stock in a transaction that occurred on Monday, April 22nd. The stock was sold at an average price of $15.00, for a total transaction of $717,810.00. Following the sale, the insider now directly owns 3,036,153 shares in the company, valued at approximately $45,542,295. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 13.70% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vivo Capital LLC acquired a new position in shares of enGene during the fourth quarter worth approximately $6,264,000. Omega Fund Management LLC bought a new stake in enGene during the 4th quarter valued at $10,441,000. BVF Inc. IL acquired a new position in enGene during the 4th quarter worth $20,777,000. Finally, Fcpm Iii Services B.V. bought a new position in shares of enGene in the fourth quarter worth $80,097,000. Institutional investors own 64.16% of the company's stock.

enGene Stock Performance

Shares of enGene stock traded down $0.17 during trading on Friday, hitting $14.23. 3,342 shares of the stock were exchanged, compared to its average volume of 108,379. enGene has a 12 month low of $6.69 and a 12 month high of $43.00. The company has a fifty day moving average of $16.14.

Analyst Ratings Changes

A number of brokerages have recently weighed in on ENGN. UBS Group started coverage on enGene in a report on Thursday, March 28th. They issued a "buy" rating and a $37.00 price target for the company. Wells Fargo & Company assumed coverage on shares of enGene in a report on Monday, April 22nd. They set an "overweight" rating and a $30.00 target price on the stock. Guggenheim initiated coverage on shares of enGene in a report on Monday, April 15th. They issued a "buy" rating and a $34.00 price target for the company. SVB Leerink assumed coverage on shares of enGene in a research note on Tuesday, February 20th. They set an "outperform" rating and a $31.00 price objective on the stock. Finally, Leerink Partnrs reissued an "outperform" rating on shares of enGene in a report on Tuesday, February 20th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $34.40.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.